Catalyst overview
Research summary
This catalyst tracks a Phase 1a data readout for DAY301 (formerly MTX-13) in Solid tumor/s. The expected timing is based on the latest available company guidance and may change.
04/2024 - FDA cleared IND. 1/13/25- First dose cohort cleared. 8/5/25- Actively enrolling participants. 11/04/25:- Dose escalation in the Ph1a trial of DAY301, a PTK7-targeted ADC, is actively advancing. 01/11/26:- Initial data from the Phase 1a DAY301 trial in H2 2026. 02/24/26:- Phase 1a DAY301 dose escalation ongoing; initial clinical data and program update planned for H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.